Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation.

Front Endocrinol (Lausanne) · 2020 · PMC7243474 · PMID 32499755

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

showed a trendp = 0.052so close (0.05 < p ≤ 0.1)

Biopsies from patients obtained during discontinuation showed a trend for reduced cortical thickness when compared to treatment-naive biopsies ( p = 0.052).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.